Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat

American Journal of Obstetrics and Gynecology

Volumn 175, Issue 3 PART I, 1996, Pages 593-599

  Rose, G Scott ^a   Tocco, Lisa M ^a   Granger, Gale A ^a   DiSaia, Philip J ^a   Hamilton, Thomas C ^b   Santin, Alessandro D ^a   Hiserodt, John C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Animal model; Fischer 344; Immunogenicity; Nutu 19; Ovarian cancer; Ovarian neoplasm

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; EPITHELIUM CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RAT; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; DISEASE MODELS, ANIMAL; EPITHELIUM; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; INJECTIONS, INTRAPERITONEAL; INTERCELLULAR ADHESION MOLECULE-1; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; RATS; RATS, INBRED F344; TUMOR CELLS, CULTURED;

EID: 0029828749     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1053/ob.1996.v175.a73595     Document Type: Article

References (25)

1. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994;44:7-26.
2. DiSaia P, Creasman W. Clinical gynecologic oncology. St. Louis: Mosby-Year Book, 1993.
3. Fu X, Hoffman RM. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res 1993;13:283-6.
4. Sekiya S, Endoh N, Kikuchi Y, Katoh T, Matsuura A, Isawa H, et al. In vivo and in vitro studies of experimental ovarian adenocarcinoma in rats. Cancer Res 1979;39:1108-12.
5. Pretorius RG, Eisenkop S, Berek JS, Hacker NF, Ashikaga T, Knox RM, et al. Utilization of a murine model to optimize volume and dwell time of intraperitoneal cisplatin. Gynecol Oncol 1989;34:66-9.
6. Ishiwata K, Tomura M, Ido T, Iwata R, Sato K, Hatazawa J, et al. 6-[18F]fluoro-L-fucose: a possible tracer for assessing glycoconjugate synthesis in tumors with positron emission tomography. J Nucl Med 1990;31:1997-2003.
7. Testa JR, Getts LA, Salazar H, Liu Z, Handel LM, Godwin AK, et al. Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. Cancer Res 1994;54:2778-84.
8. Maronpot RR. Ovarian toxicity and carcinogeniciry in eight recent National Toxicology Program studies. Environ Health Perspect 1987;73:125-30.
9. Alison RH, Morgan KT. Ovarian neoplasms in F344 rats and B6C3F1 mice. Environ Health Perspect 1987;73:91-106.
10. Lewis DJ. Ovarian neoplasia in the Sprague-Dawley rat. Environ Health Perspect 1987;73:77-90.
11. Hewitt HB. The choice of animal tumors for experimental studies of cancer therapy. Adv Cancer Res 1978;27:149-200.
12. Alison RH, Morgan KT, Haseman JK, Boorman GA. Morphology and classification of ovarian neoplasms in F344 rats and (C57BL/6 X C3H) F1 mice. J Natl Cancer Inst 1987;78: 1229-43.
13. Montgomery CA, Alison RH. Nonneoplastic lesions of the ovary in Fischer 344 rats and B6C3F1 mice. Environ Health Perspect 1987;73:53-75.
14. Snell K. Spontaneous lesions in the rat. Springfield, IL: CC Thomas, 1965.
15. Fathalla MF. Factors in the causation and incidence of ovarian cancer. Obstet Gynecol Surv 1972;27:751-68.
16. Schreiber H. Tumor immunology. In: Paul W, editor. Fundamental immunology. New York: Raven Press, 1993:1143-78.
17. Hellstrom I, Hellstrom KE. Tumor immunology: an overview. Ann N Y Acad Sci 1993;690:24-33.
18. Vanky F, Stuber G, Rotstein S, Klein E. Auto-tumor recognition following in vitro induction of MHC antigen expression on solid human tumors: stimulation of lymphocytes and generation of cytotoxicity against the original MHC-antigen-negative tumor cells. Cancer Immunol Immunother 1989; 28:17-21.
19. Chen L, McGowan P, Ashe S, Johnston JV, Hellstrom I, Hellstrom KE. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebaderium parvum. Cancer Res 1994;54:5420-3.
20. Gatanaga T, Lentz R, Masunaka I, Tomich J, Jeffes EW, Baird M, et al. Identification of TNF-LT blocking factor(s) in the serum and ultrafiltrates of human cancer patients. Lym-phokine Res 1990;9:225-9.
21. Dranoff G, Jaffee E, Lazenby A, Gulumbeck P, Leritsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90: 3539-43.
22. Kabawat SE, Bast RCJ, Welch WR, Knapp RC, Bhan AK. Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. Int J Cancer 1983;32:547-54.
23. Hammerling GJ, Klar D, Pulm W, Momburg F, Moldenhauer G. The influence of major histocompatibility complex class I antigens on tumor growth and metastasis. Biochim Biophys Acta 1987;907:245-59.
24. Ostrand-Rosenberg S, Clements VK, Thakur A, Cole GA. Transfection of major histocompatibility complex class I and class II genes causes tumour rejection. J Immunogenet 1989; 16:343-9.
25. Vanky F, Wang P, Patarroyo M, Klein E. Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro. Cancer Immunol Immunother 1990;31:19-27.